GB931147A - Sustained release pharmaceutical preparations and methods for their manufacture - Google Patents

Sustained release pharmaceutical preparations and methods for their manufacture

Info

Publication number
GB931147A
GB931147A GB3602559A GB3602559A GB931147A GB 931147 A GB931147 A GB 931147A GB 3602559 A GB3602559 A GB 3602559A GB 3602559 A GB3602559 A GB 3602559A GB 931147 A GB931147 A GB 931147A
Authority
GB
United Kingdom
Prior art keywords
saturated fatty
mono
alcohols
materials
pellets
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB3602559A
Inventor
John Anthony Hill
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Olin Corp
Original Assignee
Olin Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olin Corp filed Critical Olin Corp
Priority to GB3602559A priority Critical patent/GB931147A/en
Priority to DEO7057A priority patent/DE1175826B/en
Priority to FR809368A priority patent/FR1302362A/en
Publication of GB931147A publication Critical patent/GB931147A/en
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

A sustained release pharmaceutical preparation comprises pellets composed of (a) polyvinylpyrrolidone, (b) one or more substantially water-insoluble saturated fatty acids, saturated fatty acid esters of mono-, di- and trihydric alcohols, saturated fatty alcohols, mono- and polyalkylene glycol ethers of saturated fatty alcohols, saturated aliphatic ketones or pharmacologically acceptable sterols such materials being solid at temperatures up to 45 DEG C., and (c) a pharmacologically active material. The pellets are prepared by forming the components (a), (b) and (c) into a substantially uniform molten mass which is formed into small fluid droplets which are projected through the air until they are substantially solidified to form pellets substantially all of which pass through an 8-mesh U.S. Standard screen and are retained by a 200-mesh screen. The preparations may be used as such or incorporated into solid dosage forms, e.g. capsules. Specified pharmacologically active materials are antibiotics, e.g. penicillin G, hypnotics, e.g. barbiturates; tranquilizers, e.g. reserpine, rauwolfia alkaloids and phenothiazine derivatives; anti-histamines, e.g. 2 - p - chloro - a - (2 - dimethylaminoethyl) benzyl pyridine maleate; narcotics, e.g. codeine, narcotine, dihydrocodeinone and ethyl - 1 - methyl - 4 - phenylpiperidine - 4 - carboxylate hydrochloride. Specific examples relate to preparations comprising procaineamide hydrochloride. Specified materials of type (b) include stearic acid, stearone, glyceryl mono- and tri-stearate, arichidic, stearyl and cetyl alcohols, cholesterol, beeswax and candelilla, carnauba and castor waxes and condensation products of ethylene oxide with a polypropylene glycol.
GB3602559A 1959-10-23 1959-10-23 Sustained release pharmaceutical preparations and methods for their manufacture Expired GB931147A (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB3602559A GB931147A (en) 1959-10-23 1959-10-23 Sustained release pharmaceutical preparations and methods for their manufacture
DEO7057A DE1175826B (en) 1959-10-23 1959-11-02 Process for the manufacture of medicinal preparations for oral administration
FR809368A FR1302362A (en) 1959-10-23 1959-11-05 Process for the preparation of time-release pills

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB3602559A GB931147A (en) 1959-10-23 1959-10-23 Sustained release pharmaceutical preparations and methods for their manufacture

Publications (1)

Publication Number Publication Date
GB931147A true GB931147A (en) 1963-07-10

Family

ID=10384133

Family Applications (1)

Application Number Title Priority Date Filing Date
GB3602559A Expired GB931147A (en) 1959-10-23 1959-10-23 Sustained release pharmaceutical preparations and methods for their manufacture

Country Status (1)

Country Link
GB (1) GB931147A (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344968A (en) 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
DE19608750A1 (en) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Process for the production of fenofibrate preparations
JP2001525366A (en) * 1997-12-08 2001-12-11 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング New dosage forms containing acid-labile active compounds.
EP1297756A1 (en) * 2001-09-27 2003-04-02 Cognis Deutschland GmbH & Co. KG Spheric sterol preparations, their use and manufacture

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4344968A (en) 1978-12-09 1982-08-17 Nippon Kayaku Kabushiki Kaisha Pharmaceutical vehicle
DE19608750A1 (en) * 1996-03-06 1997-09-11 Durachemie Gmbh & Co Kg Process for the production of fenofibrate preparations
JP2001525366A (en) * 1997-12-08 2001-12-11 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング New dosage forms containing acid-labile active compounds.
EP1297756A1 (en) * 2001-09-27 2003-04-02 Cognis Deutschland GmbH & Co. KG Spheric sterol preparations, their use and manufacture
US6911164B2 (en) 2001-09-27 2005-06-28 Cognis Deutschland Gmbh & Co. Kg Spherical sterol preparations, their production and their use

Similar Documents

Publication Publication Date Title
JP2573275B2 (en) Pharmaceutical preparations and methods for their production
DE68915695T2 (en) Preparations with controlled release of active ingredients.
US5593690A (en) Sustained release preparations
US4814175A (en) Nifedipine combination preparation
DE69203488D1 (en) Low-dose dried pharmaceutical preparations.
NO881296L (en) PROCEDURE FOR PREPARING A PHARMACEUTICAL PREPARATION WITH SLOW RELEASE OF A PHARMACEUTICAL ACTIVE SUBSTANCE.
GB1027516A (en) Controlled release medicaments
JPH08505364A (en) Calcitonin-containing pharmaceutical composition
GB1030127A (en) Improvements in or relating to method of preparing sustained release pharmaceutical pellets and product thereof
EP0222411B1 (en) Method of preparing sustained-release pharmaceutical preparation
JPH044294B2 (en)
SI9111618B (en) Orally administered solvent-free pharmaceutical preparation with retarded active-substance release, and the procedure for its preparation
JPH07196513A (en) Medicinal granule
JPS63188621A (en) Flavor oral preparation
EP1396263A1 (en) Film coating for tablets and caplets
GB931147A (en) Sustained release pharmaceutical preparations and methods for their manufacture
US6558703B1 (en) Porous hydroxyapatite particles as carriers for drug substances
GB1427881A (en) Mixtures containing nitroglycerin and polyvinyl-pyrrolidone
JPS5649314A (en) Lasting pharmaceutical composition having prolonged action and its preparation
KR860006265A (en) Process for preparing sustained release preparation containing 9,10-dihydro ergot alkaloid
CN102008447A (en) Entecavir solid dispersion and preparation thereof
JPH01117825A (en) Pharmaceutical for nasal cavity and paranasal sinuses administration and use, form and use tool thereof
RU2160107C2 (en) Tablet, capsule, or granule containing desogestrel and method of preparation thereof
JPH0460090B2 (en)
JP4570725B2 (en) Composition for pharmaceutical preparation